Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$476.27 USD

476.27
490,764

+2.99 (0.63%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $476.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Looking for a Growth Stock? Why It is Time to Focus on IDEXX Laboratories (IDXX)

IDEXX Laboratories (IDXX) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.

    The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies

    The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies

      5 MedTech Stocks to Beat Tax Hazards With Positive Returns

      Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.

        Medtronic (MDT) Beats on Q2 Earnings, Reiterates FY18 View

        Medtronic (MDT) rides high on strength in major business segments in Q2.

          Patterson Companies (PDCO) Misses on Q2 Earnings, Cuts View

          Patterson Companies (PDCO) missed estimates for both the counts in Q2. A downbeat guidance indicates looming concerns.

            Accelerate Diagnostics (AXDX) in Focus: Stock Moves 6.7% Higher

            Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.

              Zacks.com highlights: Home Depot, Baxter International, IDEXX Laboratories, NVR and MAM Software Group

              Zacks.com highlights: Home Depot, Baxter International, IDEXX Laboratories, NVR and MAM Software Group

                Tirthankar Chakraborty headshot

                5 of the Most Efficient Stocks to Buy Now

                We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns.

                  DaVita Issues Downbeat '17 View, Hurricanes Affect Q3 Results

                  Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.

                    4 Top Growth Picks to Avoid Tax Tangle in MedTech

                    Despite the ongoing tax bill-related disputes in the MedTech industry, these stocks with high growth potential can be great bets for investors.

                      IDEXX Laboratories (IDXX) Q3 Earnings Beat, Revenues Miss

                      IDEXX Laboratories (IDXX) rides high on strength in Companion Animal Group business in Q3. Moreover, a raised guidance buoys optimism.

                        IDEXX Laboratories (IDXX) Beats on Q3 Earnings, View Up

                        IDEXX Laboratories (IDXX) gains on solid contributions from Companion Animal Group business in Q3.

                          Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?

                          IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                            PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up

                            The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.

                              Can Companion Animal Group Drive IDEXX's (IDXX) Q3 Earnings?

                              IDEXX Laboratories (IDXX) is poised to gain from strength in its Companion Animal Group business in Q3.

                                Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed

                                Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.

                                  Phibro Animal Banks on Diverse Portfolio, Competition Rife

                                  Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.

                                    Henry Schein (HSIC) Inks Distribution Agreement with Terason

                                    Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.

                                      Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

                                      Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

                                        Here's Why Investors Should Buy Integra LifeSciences Now

                                        The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

                                          TransEnterix Senhance Surgical Robotic System Wins FDA Nod

                                          TransEnterix (TRXC) works on expanding in robotic surgery consistently.

                                            Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

                                            Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.

                                              NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

                                              NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.

                                                Here's Why Investors Should Sell Ecolab (ECL) Right Away

                                                Intensifying competition, foreign exchange volatility, higher raw material costs and integration risks are primary headwinds for Ecolab (ECL) as of now.

                                                  Abbott Banks on FDA Approvals and Buyouts, Competition Rife

                                                  The market is upbeat about Abbott's (ABT) latest initiatives.